Press Service English
March 21, 2017
Coronary heart disease: Functional imaging helps avoid unnecessary angiography and save costs
(Vienna, March 21, 2017) Heart catheterizations for assessing coronary heart disease are often unnecessary and can be replaced with functional cardiac imaging techniques. This is the result of a large-scale study recently conducted in the UK. “Functional cardiac imaging is less risky and less costly while providing accurate and reliable results. It is a good diagnostic starting point that should serve as gatekeeper for angiography,” says Prof. Riemer H.J.A. Slart, cardiovascular expert of the European Association of Nuclear Medicine (EANM).
December 13, 2016
Prostate cancer: Identifying and destroying the tumour through nuclear medicine therapy
(Vienna, December 13, 2016) Prostate cancer patients who are resistant to hormone treatment used to have a poor prognosis. Until recently, the diagnostic and therapeutic possibilities had been limited, but now innovative developments in nuclear medicine imaging and therapy open up promising pathways. Novel substances used with PET/CT (positron-emission tomography combined with computed tomography) not only allow for better diagnosis but also offer treatment options where other therapies have failed. “This offers a glimpse of hope to patients who suffer from this particularly severe form of prostate cancer,” says EANM expert Prof. Markus Luster.
September 6, 2016
Myocardial nuclear imaging: Minimizing the dose – preserving the diagnostic value
(Vienna, September 6, 2016) Cardiac scintigraphy plays an important role in the evaluation of patients with a suspicion or known coronary artery disease (angina pectoris, myocardial infarction), but submitted patients to higher levels of radiations in comparison to other imaging techniques. New detection systems (CZT cameras) have become available that offer to reduce dramatically the level of radiations associated to cardiac scintigraphy. “Using these new systems, we can provide cardiologists with critical information on the status of the vessels supplying blood within the heart and expose patients to only minimal levels of radiations ,” says Dr. Fabien Hyafil, expert of the European Association of Nuclear Medicine (EANM).
July 26, 2016
Alzheimer’s disease: Pinpointing destructive tau tangles through novel imaging technique
(Vienna, July 26, 2016) New nuclear imaging techniques help to detect a key factor involved in Alzheimer’s disease (AD) much earlier and more precisely than before. Recently developed tracers, used with positron emission tomography (PET) make tau tangles in the brain visible. For the first time these deposits which cause severe neuronal malfunctions can be identified and investigated “live” in the brains of AD patients long before the onset of noticeable mental impairment. “This is an important step towards our goal to develop efficient drugs to fight and eventually cure AD”, says Dr Silvia Morbelli, expert of the European Association of Nuclear Medicine (EANM).
November 5, 2015
Conditions in 2016 for reliable and sustainable supply of medical radioisotopes
AIPES is pleased to report on the recent demands regarding the supply of medical radioisotopes produced in reactor and more specifically Mo-99.
November 5, 2015
Cardiovascular diseases: Detecting dangerous plaques in time
(Vienna, November 5, 2015) With 5 million deaths per year cardiovascular diseases (CVD) are the leading cause of mortality in Europe. In western countries over a third of the adults die from coronary artery disease and another 25 % from stroke. Unstable plaques in arteries , which play a significant role in CVD,often remain undetected until a dangerous stage has been reached. “Novel nuclear imaging techniques now enable us to identify these ‘time bombs’ much earlier and raise hope to be able to prevent them from becoming a threat to the patient’s life,” says Dr. Fabien Hyafil, expert of the European Association of Nuclear Medicine (EANM).
July 13, 2015
Paediatric nuclear imaging: Minimizing the dose – maintaining the diagnostic value
The amount of radiation children are exposed to when undergoing nuclear medical examinations will be further reduced. This is due to new international guidelines that have been jointly set up by the European Association of Nuclear Medicine (EANM) and North American scientific societies.
April 21, 2015
Tumor therapy: Making the right choice
For tumor patients the timely choice of the appropriate therapy is of vital importance. Nuclear medical methods such as PET (positron emission tomography) allow not only for targeting the tumor but also for assessing the treatment outcome soon after therapy onset. This enables doctors to change treatment if necessary and adapt it to the specific conditions and needs of their patients, says Prof. Stefano Fanti, expert of the European Association of Nuclear Medicine (EANM).
April 9, 2015
5.500 nuclear medicine specialists will be in Hamburg this October
Hamburg is the host city of the 28th EANM Congress. The annual event of the European Association of Nuclear Medicine (EANM) takes place from October 10 to October 14, 2015 in the Congress Centre Hamburg (CCH). Around 5.500 international visitors are expected to attend this year’s congress, including mainly specialists in the field of Nuclear medicine.
Download Press Release (german)
February 27, 2015
AIPES announces the nuclear medicine Press & Media Award
AIPES is pleased to announce the Press & Online Media Award. This award will be for the best published article or online media feature between August 2014 and July 2015.
January 20, 2015
Prostate cancer: Novel radiopharmaceuticals prolong survival of patients with bone metastases
At an advanced stage prostate cancer frequently leads to bone metastases which may result in pain, fractures, and disability and are associated with a poor prognosis. Recently a major breakthrough has been achieved which is about to improve the patients’ situation, as Prof. Markus Luster, expert of the European Association of Nuclear Medicine (EANM), points out: “Radium-223-dichloride is the first bone-targeted drug that not only alleviates symptoms but also prolongs the life expectancy of these patients. Study results give us reason to believe that this is a promising path in the treatment of bone metastases linked to prostate cancer and potentially to other tumour types.”